May 19th 2025
The LP.8.1 variant of the SARS-CoV-2 virus differs from the JN.1 family that previous vaccines had been designed to target, and has surpassed JN.1 as the variant circulating most widely worldwide.
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Investigating Inhalation Forms and Drug Delivery with Shabbir Mostafa (DCAT Week)
May 19th 2023Shabbir Mostafa, head of Business Development — Advanced Delivery Systems, Recipharm, sat down with Grant Playter, associate editor, during DCAT week to discuss the current state of inhalations forms and drug delivery.
Discussing Oligonucleotides, Sustainability, and Yams with Rafael Antunes (DCAT Week)
April 22nd 2023Rafael Antunes, vice-president of Business Development Europe at Aurisco, speaks about his company's recent efforts in the field of oligonucleotides, its partnership with Cytiva, and its broader sustainability efforts.